Adagene Inc.
- ADAG
- NASDAQ
- Biotechnology
- Cancer Immunotherapy
- Monoclonal Antibodies
$2.06
Today −14.17%Quote Oct 16, 2026, 08:00 PM UTC
−38.87%over the last month
Max drawdown −38.9%From 1-month high −38.9%3 months −43.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$122.0M
Quote Oct 16
Next earnings
Mar 31
Expected, not confirmed
Analyst target
$8.67
+320.9% from here
Floor
$1.91
7.3% below price
Where the price sits
5 analysts
Analyst range, low to high
$7.00$10.00
- Price $2.06
- Resistance $2.09
- Consensus $8.67
The price is right under resistance. Analysts' average target sits about 321% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ADAGPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
128
Founded
2011